Doctor's DEA Bid Sinks Over Missed Hearing Deadlines
Published Date: 4/16/2025
Notice
Summary
Dr. Moustafa M. Aboshady’s application to register with the DEA in Salt Lake City was denied because he’s barred from federal health programs like Medicare and Medicaid. He asked for a hearing but missed key deadlines to respond properly, so the DEA moved forward without his full defense. This means he can’t legally handle controlled substances, affecting his medical practice and income starting early 2024.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Denied for Dr. Aboshady
The Drug Enforcement Administration denied Moustafa M. Aboshady, M.D.'s pending application for a DEA Certificate of Registration (Control No. W23147064C). The Order denying his application, and any other pending application for additional registration in Utah, is effective May 16, 2025.
Found Excluded from Federal Health Programs
The record shows that HHS/OIG mandatorily excluded Dr. Moustafa M. Aboshady from participation in Medicare, Medicaid, and all Federal health care programs pursuant to 42 U.S.C. 1320a-7(a) for a minimum of 15 years. That exclusion became effective August 30, 2019 and was a basis for the DEA's denial under 21 U.S.C. 824(a)(5).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06425, Empire Pharmacy Inc.; Skyline Pharmacy Inc.; Decision and Order
Empire Pharmacy and Skyline Pharmacy in Philadelphia lost their DEA registrations because they didn’t keep proper records of controlled substances, which could risk public safety. Their registrations were suspended immediately, and since they didn’t ask for a hearing, the suspension and revocation are now final. This means they can’t legally handle controlled drugs anymore, affecting their business and customers starting now.
Next: 2025-06427, Lona Bibbs-Walker, D.D.S.; Decision and Order
Dr. Lona Bibbs-Walker's license to handle controlled substances is officially suspended and set for revocation because she lost track of many drugs and lost her state dental license. Since she didn’t ask for a hearing, the DEA is moving forward with shutting down her registrations, protecting public safety. This means she can’t legally prescribe or handle controlled substances anymore, effective immediately.